Atara Biotherapeutics

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Atara Biotherapeutics strengthens financial position and advances clinical milestones

Atara Biotherapeutics is strategically positioned to drive growth through financial stability, pipeline advancements, and operational efficiency.
Despite workforce reductions, the company's focus on key clinical milestones and regulatory milestones bodes well for future revenue potential.
Navigating challenges in workforce restructuring and regulatory hurdles, Atara remains focused on leveraging opportunities in CAR-T therapies and autoimmune diseases.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

THOUSAND OAKS, Calif.--( BUSINESS WIRE )--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, has entered into a royalty interest financing agreement totaling $31 million with HealthCare Royalty (HCRx) for Ebvallo™ in Europe and other territories covered by Atara's commercialization agreement with Pierre Fabre.

Atara Biotherapeutics Announces $31 Million Royalty Interest Financing Agreement with HealthCare Royalty

THOUSAND OAKS, Calif.--( BUSINESS WIRE )--Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced that Carol Gallagher will assume the role of Chair of the Board of Directors, replacing Ron Renaud, who is stepping down to focus on his new position as Managing Director at Bain Capital Life Sciences.

Atara Biotherapeutics Announces Changes to Its Board of Directors

THOUSAND OAKS, Calif. & CASTRES, France--( BUSINESS WIRE )--Atara Biotherapeutics, Inc. (Nasdaq: ATRA) and Pierre Fabre today announced that the European Commission (EC) has granted marketing authorization for Ebvallo™ (tabelecleucel) as a monotherapy for the treatment of adult and pediatric patients two years of age and older with relapsed or refractory Epstein‑Barr virus positive post‑transplant lymphoproliferative disease (EBV+ PTLD) who have received at least one prior therapy. For solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate.

Atara Biotherapeutics' Ebvallo™ (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLD

Atara Biotherapeutics has complications with the FDA while the EU approach is so much clearer. The MS drug is a value driver if ATRA sorts out issues.

Consider Atara Biotherapeutics As The Tab-Cel Delay Resolves In The U.S.

THOUSAND OAKS, Calif.--( BUSINESS WIRE )--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced updated interim analysis and safety results from its Phase 3 multicenter ALLELE study investigating tabelecleucel (tab-cel®) for the treatment of relapsed/refractory (r/r) Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) following solid organ transplant (SOT) or hematopoietic cell transplant (HCT).

Atara Biotherapeutics Presents Updated Clinical Data from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 64th American Society of Hematology (ASH) Annual Meeting

THOUSAND OAKS, Calif.--( BUSINESS WIRE )--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a virtual fireside chat at the Evercore ISI 5th Annual HealthCONx Conference on Wednesday, November 30, 2022, at 2:15 p.m. EST.

Atara Biotherapeutics to Participate at the Evercore ISI 5th Annual HealthCONx Conference

Atara Biotherapeutics to Participate at the Stifel Healthcare Conference

Atara Biotherapeutics, Inc. (NASDAQ:ATRA ) Q3 2022 Results Conference Call November 8, 2022 4:30 PM ET Company Participants Eric Hyllengren - Vice President of Investor Relations and Finance Dr. Pascal Touchon - President and Chief Executive Officer Dr. Jakob Dupont - Executive Vice President and Global Head of Research and Development Utpal Koppikar - Chief Financial Officer Dr. AJ Joshi - Chief Medical Officer Conference Call Participants Salim Syed - Mizuho Group John Newman - Canaccord Phil Nadeau - Cowen and Company Kallie Briza - Stifel Jessica Hui - Evercore Operator Good afternoon, everyone. Thank you for standing by, and welcome to the Atara Biotherapeutics Third Quarter 2022 Financial Results Conference Call.

Atara Biotherapeutics, Inc. (ATRA) Q3 2022 Earnings Call Transcript

Atara Biotherapeutics Announces Third Quarter 2022 Financial Results and Operational Progress

Atara Biotherapeutics to Announce Third Quarter 2022 Financial Results on Tuesday, November 8, 2022

Atara Biotherapeutics Presents New MRI and Updated Open-Label Extension Data from Phase 1 Study of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2022

Acorda Therapeutics

Atossa Genetics

PAVmed

Xeris Biopharma Holdings

Biotech penny stocks for your watch list this week. The post Best Penny Stocks To Buy?

Best Penny Stocks To Buy? 5 Biotech Stocks For Your Watch List This Week

CHMP Recommends Approval of Atara Biotherapeutics' Ebvallo™ (tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, today announced an update to its existing collaboration agreement with Pierre Fabre for the commercialization of tabelecleucel (tab-cel®) for Epstein-Barr virus (EBV)-positive cancers. Under the amended terms, Atara will receive an additional USD 30 million milestone payment upon tab-cel® EC approval and subsequent filing of the Marketing Authorization Application (MAA) tr

Atara Biotherapeutics to Receive Additional Near-Term Milestone Payment Under Updated Tabelecleucel (Tab-cel®) Commercialization Agreement with Pierre Fabre

Cardlytics

Forge Global Holdings Inc

Energy Vault Holdings

REX American Resources

Rhythm Pharmaceuticals

Cassava Sciences Inc

SQL Technologies Corp

Target Hospitality Corp

Velo3D

So far, 2022 has been rough for small-cap stocks. These stocks, however, often have more upside than large-cap stocks, especially during a bull market.

These Were the Five Best and Worst Performing Small-Cap Stocks in August 2022

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a cell therapy panel discussion at the Citigroup 17th Annual Biopharma Conference on Wednesday, September 7, 2022 at 6:4

Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Citigroup 17th Annual Biopharma Conference

Aditxt Inc

Doma Holdings

Are you using these trends to make money with penny stocks? The post Stock Market Trends, Penny Stocks in 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Stock Market Trends, Penny Stocks in 2022

BARK

Sonder Holdings

Penny stocks to buy or avoid? 3 for your watch list right now.

Penny Stocks To Buy Now? 3 To Watch After NERV Stock Explodes 160%

NRG Energy

Seritage Growth Properties

The small-cap Russell 2000 gained over 10% in July, compared to a jump of 9.1% for the S&P 500.

These Are The Ten Best And Worst Performing Small-Cap Stocks In July 2022

Atara has two possible regulatory approvals for tab-cel for PTLD; European approval expected Q4 of 2022 and BLA filing for U.S. territory to be updated in next quarter earnings call. Two data readouts of ATA188 for treatment of patients with progressive multiple sclerosis; Phase 1 MRI Data/OLE data Q4 2022 and phase 2 EMBOLD study data expected October 2023.

Atara: 2 Possible Regulatory Approvals For Tab-Cel, Plus CAR T Pipeline

The mean of analysts' price targets for Atara Biotherapeutics (ATRA) points to a 204.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Does Atara Biotherapeutics (ATRA) Have the Potential to Rally 204% as Wall Street Analysts Expect?

Atara Biotherapeutics, Inc. (NASDAQ:ATRA ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Eric Hyllengren - VP of IR and Finance Pascal Touchon - President and CEO Utpal Koppikar - CFO Jakob Dupont - EVP and Global Head of Research and Development AJ Joshi - Chief Medical Officer Conference Call Participants Salim Syed - Mizuho Tessa Romero - JPMorgan John Newman - Canaccord Ernesto Rodriguez Dumont - Cowen & Co. Michael DiFiore - Evercore ISI Tommie Reerink - Goldman Sachs Carly Kenselaar - Citi Operator Greetings, and welcome to Atara Biotherapeutics Q2 2022 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q2 2022 Results - Earnings Call Transcript

Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 65.93% and 483.28%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Atara Biotherapeutics (ATRA) Reports Q2 Loss, Tops Revenue Estimates

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the second quarter 2022, an update to its corporate strategy, recent business highlights, and key upcoming catalysts. “We are excited about the transformative potential of ATA188 in MS and are pleased

Atara Biotherapeutics Announces Second Quarter 2022 Financial Results and Corporate Strategy Update

NEW YORK--(BUSINESS WIRE)-- #ATRA--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Atara Biotherapeutics, Inc. (“Atara” or the “Company”) (NASDAQ: ATRA) on behalf of Atara stockholders. Our investigation concerns whether Atara has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On November 4, 2021, Atara issued a press release touting its T c

ATARA ALERT: Bragar Eagel & Squire, P.C. is Investigating Atara Biotherapeutics, Inc. on Behalf of Atara Stockholders and Encourages Investors to Contact the Firm

News for Atara Biotherapeutics Stock (ATRA)